Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.

Biotechnology

Design

Health Care

Pharmaceutical

Therapeutics

Elevar Therapeutics

Saeho Chong

Dr. Natalia Raphael

William Hahne, MD

Laura Alexander M.D., M.S.

Heidi Schueller

Ilija Ivancevic

Neena Chevalier, PMP

Candice Athans

Wade Smith

Tyler Wiseman

Seong Jang

Michael Palucki

Jenny Gizzi

Dominick DiPaolo, CQA CQE

Diana Heintzman

The Leadership Team at Elevar Therapeutics is responsible for guiding the strategic direction and overall operations of the company. This cross-functional team, composed of executives from key areas such as quality, manufacturing, clinical data management, legal, finance, and human resources, collaborates to ensure the successful development and commercialization of innovative cancer therapies while addressing regulatory requirements and market needs. Their leadership fosters a culture of excellence and drives the mission to meet unmet medical needs in oncology.

Leadership Team

Clinical Data Management Team

Finance and Accounting

Leadership Team

About

Team members

Other teams at Elevar Therapeutics

Clinical Data Management Team

Finance and Accounting